CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial
Posted on: Tuesday, 9 September 2008, 09:00 CDT
LAS VEGAS, Sept. 9 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (BULLETIN BOARD: CVBT) today announces that its first US site is open for patient enrollment for its Phase II clinical trial for the treatment of severe coronary heart disease. In the coming weeks, CVBT anticipates announcing additional sites as they open for enrollment. For current details about the clinical sites participating in CVBT's Phase II heart trial, please visit http://www.cvbt.com/.
In this Phase II trial, CVBT's drug candidate containing human Fibroblast Growth Factor-1 (FGF-1), will be injected into patients' hearts, stimulating a healing process called angiogenesis. The drug will be delivered using the NOGA(R) XP Cardiac Navigation system and the MyoStar(TM) injection catheter.
Subjects must be between 25 and 75 years of age with at least a 3 month history of chronic stable angina triggered by physical exertion and must have a Canadian Cardiovascular Society (CCS) anginal classification III or IV while receiving optimal medical therapy. Their treating cardiologist will have determined that they are generally not suitable for interventional therapy or bypass surgery.
"Developing a clinical trial protocol such as ours takes an extraordinary amount of time and effort, and I am pleased to finally open our Phase II heart trial for patient screening," said Daniel C. Montano, CVBT's President and CEO. "I expect additional investigators at other hospitals to begin screening patients in the coming weeks. Our target is 30 hospitals for this international Phase II heart trial."
About CardioVascular BioTherapeutics
CVBT (BULLETIN BOARD: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetics and in patients suffering from peripheral artery disease of the legs. An additional study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit http://www.cvbt.com/.
For media inquiries please contact: Allison Caplan, (702) 839-7200 acaplan@cvbt.com For investor inquiries please contact: Investor Relations, (702) 839-7220 investorrelations@cvbt.com
CardioVascular BioTherapeutics, Inc.
CONTACT: Media Inquiries, Allison Caplan, +1-702-839-7200,acaplan@cvbt.com, or Investor Relations, investorrelations@cvbt.com,+1-702-839-7220, both of CardioVascular BioTherapeutics, Inc.
Web site: http://www.cvbt.com/
Source: PRNewswire-FirstCall
Related Articles
- American Heart Association Late-Breaking Clinical Trial Report: Tailoring Drug Dose to Heart Failure Patients' Response More Effective
- American Heart Association Late Breaking Clinical Trial Report: High Dose of Angiotensin Receptor Blockers Effective in Heart Failure Patients
- Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure
- AVEO Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of AV-951 in Patients With Metastatic Renal Cell Carcinoma
- Texas Heart(R) Institute at St. Luke's Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient With a Special Stem Cell Type
- Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
- Medicure Announces Top-Line Results From Pivotal Phase 3 MEND-CABG II Clinical Trial
- Poniard Pharmaceuticals Announces Positive Preliminary Bioavailability Data From Ongoing Phase 1 Trial of Oral Picoplatin in Patients With Solid Tumors
- Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
- Biomira Initiates Phase 1 Trial of PX-478 in Patients With Advanced Metastatic Cancers
 |
 |
User Comments (0)
RSS Feeds